|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, D-30625 Hannover; and 2Department of Medicine, Humboldt University, Charité Campus Mitte, D-10117 Berlin, Germany
Submitted 3 November 2003 ; accepted in final form 2 March 2004
Adiponectin is a novel adipocytokine negatively correlated with parameters of the metabolic syndrome, such as body mass index (BMI), body fat mass (BFM), and circulating insulin levels. Furthermore, metabolic actions directly on the liver have been described. The aim of the present study was to characterize circulating adiponectin levels, hepatic turnover, and the association of adiponectin with key parameters of hepatic as well as systemic metabolism in cirrhosis, a catabolic disease. Circulating adiponectin levels and hepatic turnover were investigated in 20 patients with advanced cirrhosis. Hepatic hemodynamics [portal pressure, liver blood flow, hepatic vascular resistance, indocyanine green (ICG) half-life], body composition, resting energy expenditure, hepatic free fatty acids (FFA) and glucose turnover, and circulating levels of hormones (catecholamines, insulin, glucagon) and proinflammatory cytokines (IL-1
, TNF-
, IL-6) were also assessed. Circulating adiponectin increased dependently on the clinical stage in cirrhosis compared with controls (15.2 ± 1.7 vs. 8.2 ± 1.1 µg/ml, respectively, P < 0.01), whereas hepatic extraction decreased. Adiponectin was negatively correlated with parameters of hepatic protein synthesis (prothrombin time: r = 0.62, P = 0.003; albumin: r = 0.72, P < 0.001) but not with transaminases or parameters of lipid metabolism. In addition, circulating adiponectin increased with portal pressure (r = 0.67, P = 0.003), hepatic vascular resistance (r = 0.60, P = 0.008), and effective hepatic blood flow (ICG half-life: r = 0.69, P = 0.001). Adiponectin in cirrhosis was not correlated with BMI, BFM, parameters of energy metabolism, insulin levels, hepatic FFA and glucose turnover, and circulating proinflammatory cytokines. These results demonstrate that 1) adiponectin plasma levels in cirrhosis are significantly elevated, 2) the liver is a major source of adiponectin extraction, and 3) adiponectin levels in cirrhosis do not correlate with parameters of body composition or metabolism but exclusively with reduced liver function and altered hepatic hemodynamics.
hepatic turnover; hepatic venous pressure gradient; calorimetry; body composition
This article has been cited by other articles:
![]() |
J. F. de Boer, M. J. Bahr, K. H. W. Boker, M. P. Manns, and U. J. F. Tietge Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis Am J Physiol Gastrointest Liver Physiol, February 1, 2009; 296(2): G196 - G201. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Bahr, J. Ockenga, K. H. W. Boker, M. P. Manns, and U. J. F. Tietge Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E199 - E206. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nakano, S. Tajima, A. Yoshimi, H. Akiyama, M. Tsushima, T. Tanioka, T. Negoro, M. Tomita, and T. Tobe A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin J. Lipid Res., July 1, 2006; 47(7): 1572 - 1582. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Pagano, G. Soardo, W. Esposito, F. Fallo, L. Basan, D. Donnini, G. Federspil, L. A Sechi, and R. Vettor Plasma adiponectin is decreased in nonalcoholic fatty liver disease Eur. J. Endocrinol., January 1, 2005; 152(1): 113 - 118. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |